Clinical Development, Development and Drugs - Clinical Research Informer

Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development

pharmaphorum

MARCH 7, 2024

Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development Mike.Hammerton Thu, 07/03/2024 - 09:43 Bookmark this

Clinical Development

Clinical Development Manufacturing Development Drugs

Adcentrx raises funds to advance ADCs into clinical development

Pharmaceutical Technology

APRIL 26, 2023

Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.

Clinical Development

Clinical Development Development Clinical Trials Clinical Trials

Ablaze Pharmaceuticals to develop drug candidate for liver cancer

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China.

Development

Development Drugs Clinical Development Licensing

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Remote-controlled robotic labs.

Development

Development Drugs Pharma Companies Life Science

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs. A recent draft from the FDA provides valuable insight.

Clinical Research

Researchers develop CRISPR-based drug candidate for microbiome targeting

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The US Food and Drug Administration has granted fast-track designation to SNIPR001, which is currently in clinical development.

Development

Development Bacteria Research Gene Editing

Acute lymphocytic leukaemia leads in cell therapy clinical development

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands.

Clinical Development

Clinical Development Development Production Sales

BioMed X and Sanofi partner to leverage AI for drug development

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Development

Development Drugs In-Vivo Engineer

ImmunoForge expands agreement with Duke University for drug development

Pharmaceutical Technology

MAY 19, 2023

ImmunoForge has expanded its licence agreement with Duke University in North Carolina, US, to jointly improve research and drug development opportunities. ImmunoForge chief technology officer Dr Jim Balance pioneered the clinical development of peptide drugs genetically fused to ELPs.

Development

Development Drugs Licensing Licensing

Diversity, Equity, and Inclusion Data Service for clinical development

Drug Discovery World

SEPTEMBER 6, 2023

“Without diverse patient cohorts that accurately reflect the patient population a drug is intended for, we cannot ensure that drugs will be fully safe or effective. It’s clear the industry needs a new approach to deliver more equitable treatments, and our partnership with Krystelis will deliver this.

Clinical Development

Clinical Development Development Clinical Trials Clinical Trials

Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury

Pharma Mirror

JUNE 23, 2021

Vectura Group plc, an industry leading inhalation CDMO, today announced it has signed an agreement with Incannex Healthcare Limited, an Australian cannabinoid medicines development company, to provide pre-clinical development services for IHL-216A, Incannex’s proprietary inhaled drug product for the treatment of traumatic brain injury (TBI).

Clinical Development

Clinical Development Development Manufacturing Medicine

US FDA launches lupus consortium to confront drug development challenges

Pharmaceutical Technology

MARCH 30, 2023

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research and the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) have launched the Lupus Research Alliance (LRA) in a bid to advance research for the condition. Asian, Hispanic, and Native American women are also at higher risk.

Development

Development Drugs FDA Approval Clinical Development

Insilico Medicine appoints Sujata Rao, M.D., as Senior Vice President to oversee clinical development

Scienmag

JULY 19, 2022

July 19, 2022, New York—Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI) driven drug discovery company, has appointed Dr. Sujata Rao as Senior Vice President (SVP) with responsibility for the global clinical development strategy of Insilico Medicine’s therapeutic programs.

Clinical Development

Clinical Development Medicine Development Drugs

Abzena, Alira Health and Oncodesign launch DRIVE Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Pharma Mirror

FEBRUARY 25, 2022

This joint service offering, DRIVE™-Biologics, will leverage Abzena’s strength in design and developability, and cell line development through to commercial manufacturing.

Clinical Development

Clinical Development Development Manufacturing Medicine

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development

Development Drugs Bioavailability Production

FDA grants orphan drug designation to MAIA’s glioblastoma agent

Pharmaceutical Technology

NOVEMBER 13, 2023

As per the company, the candidate THIO, is the only direct telomere-targeting agent currently in clinical development.

Clinical Development

Clinical Development Drugs Development

SimBioSys and General Inception unite to revolutionize cancer drug development

Outsourcing Pharma

APRIL 3, 2024

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

Development

Development Drugs Clinical Development

Quotient Science's Vanessa Zann on the company's fascinating updates in drug development

BioPharma Reporter

APRIL 8, 2024

In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.

Development

Development Drugs Research Clinical Development

New podcast: Revolutionary technology for drug discovery and development

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development

Development Drugs Genome Genomics

SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. The post SOPHiA GENETICS and AstraZeneca partner for oncology drugs development appeared first on Pharmaceutical Technology.

Genetics

Genetics Development Drugs Genome

Sosei to regain rights to IBD drug after GSK discontinues programme

Pharmaceutical Technology

NOVEMBER 24, 2023

The Sosei Heptares oral IBD drug was first licensed to GSK in 2020 and is currently in Phase I clinical development.

Licensing

Licensing Licensing Drugs Clinical Development

Cancer Research UK and the KWF Dutch Cancer Society enter partnership to bring multiple drugs into clinical development

Drug Discovery Today

NOVEMBER 7, 2023

Cancer Research UK, and the KWF Dutch Cancer Society (KWF), two of the world’s largest charitable funders of cancer research, announce a new multi-project strategic partnership to advance promising therapeutic agents for cancer through early clinical development.

Clinical Development

Clinical Development Development Research Drugs

Astellas and Sutro partner to develop immunostimulatory ADCs

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). Astellas and Sutro will expedite the development of iADCs for three different biological targets.

Development

Development Antibody Immune Response Production

€25 million to support clinical developments against Long Covid

Drug Discovery World

MARCH 8, 2023

The first €7 million of this funding contributes to the development of the Phase II clinical study in Long Covid, the first results of which should be available by the end of this year.” The post €25 million to support clinical developments against Long Covid appeared first on Drug Discovery World (DDW).

Clinical Development

Clinical Development Development Vaccination Vaccine

Astellas to support development of Taysha’s gene therapy programmes

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy

Gene Therapy Gene Development Genetics

Forge Biologics joins BGTC for new AAV gene therapies development

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy

Gene Therapy Gene Development Manufacturing

Opinion: Drug developers navigating ‘biology’s century’ need a model. We made one

STAT News

MARCH 15, 2023

STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry is “not prepared for the next wave of biotech innovation.” ” His report ends on a somewhat dismal note: the industry is long on diagnosis (clinical development is too expensive) and short on cures.

Development

Development Drugs Clinical Development

Astellas and Cullgen to develop small molecule protein degraders

Pharmaceutical Technology

JUNE 15, 2023

Japan-based Astellas Pharma has entered a partnership with Cullgen to discover and develop multiple targeted protein degraders through the latter’s proprietary uSMITE targeted protein degradation platform, in a deal potentially worth $1.9bn. Astellas could pay Cullgen up to $85m upon using its license option regarding the deal.

Protein

Protein Development Licensing Licensing

Revolutionary technology for drug discovery and development

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development

Development Drugs Genome Genomics

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

SEPTEMBER 23, 2022

While a handful of therapies have launched since then, late-stage pipeline therapies that are currently in development reveal that drug developers are exploring a broad set of mechanisms of action (MOAs), many of which are innovative, to tackle DES.

Development

Development Drugs Clinical Trials Clinical Trials

TORL scores $158m in Series B2 to advance ADC cancer therapies

Pharmaceutical Technology

APRIL 10, 2024

TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.

Clinical Development

Clinical Development Antibody Development Drugs

Repurposed Drugs by Luminous Mind for Depression: Likelihood of Approval

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Depression.

Drugs

Drugs Clinical Development Development

Repurposed Drugs by Luminous Mind for Depression: Likelihood of Approval

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Depression.

Drugs

Drugs Clinical Development Development

Repurposed Drugs by Luminous Mind for Anxiety Disorders: Likelihood of Approval

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Anxiety Disorders.

Drugs

Drugs Clinical Development Development

Repurposed Drugs by Luminous Mind for Anxiety Disorders: Likelihood of Approval

Pharmaceutical Technology

JANUARY 22, 2024

Repurposed Drugs is under clinical development by Luminous Mind and currently in Phase I for Anxiety Disorders.

Drugs

Drugs Clinical Development Development

Quotient Science's Vanessa Zann on the company's fascinating updates in drug development

BioPharma Reporter

APRIL 8, 2024

In an exclusive interview with Dr Vanessa Zann, (pictured below) executive drug development consultant at Quotient Sciences, OSP delved into the forefront of pharmaceutical research and development.

Development

Development Drugs Research Clinical Development

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

BioTech 365

JULY 14, 2021

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development CHENGDU, China–(BUSINESS WIRE)–#cancer–Anticancer Bioscience (ACB), pioneers … Continue (..)

Clinical Development

Clinical Development Development Drugs

HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald

XTalks

OCTOBER 4, 2023

How is the shift toward value-based healthcare affecting drug pricing and reimbursement? There is a world where the way we have done things up until now from a pricing, health economics and access perspective is well-suited to meet the needs of drug reimbursement stakeholders, and where we would probably keep doing it.

Marketing

Marketing Development Drugs Gene Therapy

2023 cancer research highlights: Drug development at its best

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong.

Development

Development Research Drugs Antibody

SiteOne secures funding from NIDA for non-opioid therapy development

Pharmaceutical Technology

MAY 19, 2023

SiteOne Therapeutics has received a $15m grant from the National Institute on Drug Abuse (NIDA) to develop the investigational selective NaV1.8 Titled ‘Development of a potent and selective Nav1.8 The company stated that the grant from NIDA will support the clinical development of its NaV1.8

Development

Development Clinical Development Regulation Drugs

The Power of Personalization Amid the Changing CRO Landscape

Worldwide Clinical Trials

DECEMBER 7, 2023

These survey results also highlight the importance of evaluating a variety of potential CRO partners of different sizes to choose the best match for your clinical development goals and corporate culture. At Worldwide, we understand that every program is different, which means every drug development path forward will be unique.

Clinical Development

Clinical Development Clinical Trials Clinical Trials Trials

Brii Biosciences Provides Update on Strategic Clinical Development Progress

BioTech 365

MAY 17, 2021

Brii Biosciences Provides Update on Strategic Clinical Development Progress Brii Biosciences Provides Update on Strategic Clinical Development Progress Company received U.S.

Clinical Development

Clinical Development Development Drugs

Prostate Cancer Drug Development Summit

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Download the full event guide to learn more.

Development

Development Drugs Clinical Development

Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”

Antibody

Antibody Drugs Clinical Development Licensing

Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development

Adcentrx raises funds to advance ADCs into clinical development

Trending Sources

Ablaze Pharmaceuticals to develop drug candidate for liver cancer

Cloud robotics labs are accelerating drug discovery and development

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Researchers develop CRISPR-based drug candidate for microbiome targeting

Acute lymphocytic leukaemia leads in cell therapy clinical development

BioMed X and Sanofi partner to leverage AI for drug development

ImmunoForge expands agreement with Duke University for drug development

Diversity, Equity, and Inclusion Data Service for clinical development

Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Traumatic Brain Injury

US FDA launches lupus consortium to confront drug development challenges

Insilico Medicine appoints Sujata Rao, M.D., as Senior Vice President to oversee clinical development

Abzena, Alira Health and Oncodesign launch DRIVE Biologics to support access to specialist services from discovery to clinical development for oncology and inflammation

Zerion and Insud to develop Dispersome formulations of drugs

FDA grants orphan drug designation to MAIA’s glioblastoma agent

SimBioSys and General Inception unite to revolutionize cancer drug development

Quotient Science's Vanessa Zann on the company's fascinating updates in drug development

New podcast: Revolutionary technology for drug discovery and development

SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

Sosei to regain rights to IBD drug after GSK discontinues programme

Cancer Research UK and the KWF Dutch Cancer Society enter partnership to bring multiple drugs into clinical development

Astellas and Sutro partner to develop immunostimulatory ADCs

€25 million to support clinical developments against Long Covid

Astellas to support development of Taysha’s gene therapy programmes

Forge Biologics joins BGTC for new AAV gene therapies development

Opinion: Drug developers navigating ‘biology’s century’ need a model. We made one

Astellas and Cullgen to develop small molecule protein degraders

Revolutionary technology for drug discovery and development

Drug developers look at innovative mechanisms to tackle dry eye syndrome

TORL scores $158m in Series B2 to advance ADC cancer therapies

Repurposed Drugs by Luminous Mind for Depression: Likelihood of Approval

Repurposed Drugs by Luminous Mind for Depression: Likelihood of Approval

Repurposed Drugs by Luminous Mind for Anxiety Disorders: Likelihood of Approval

Repurposed Drugs by Luminous Mind for Anxiety Disorders: Likelihood of Approval

Quotient Science's Vanessa Zann on the company's fascinating updates in drug development

Anticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development

HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald

2023 cancer research highlights: Drug development at its best

SiteOne secures funding from NIDA for non-opioid therapy development

The Power of Personalization Amid the Changing CRO Landscape

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Prostate Cancer Drug Development Summit

Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate

Stay Connected